Robert J Fox, Bruce A C Cree, Jérôme de Sèze, Ralf Gold, Hans-Peter Hartung, Douglas Jeffery, Ludwig Kappos, Xavier Montalban, Bianca Weinstock-Guttman, Carol M Singh, Arman Altincatal, Nicholas Belviso, Robin L Avila, Pei-Ran Ho, Ray Su, Robert Engle, Dipen Sangurdekar, Carl de Moor, Elizabeth Fisher, Bernd C Kieseier, Richard A Rudick
BACKGROUND AND OBJECTIVES: Serum neurofilament light chain (sNfL) levels correlate with multiple sclerosis (MS) disease activity, but the dynamics of this correlation are unknown. We evaluated the relationship between sNfL levels and radiologic MS disease activity through monthly assessments during the 24-week natalizumab treatment interruption period in RESTORE (NCT01071083). METHODS: In the RESTORE trial, participants with relapsing forms of MS who had received natalizumab for ≥12 months were randomized to either continue or stop natalizumab and followed with MRI and blood draws every 4 weeks to week 28 and again at week 52 The sNfL was measured, and its dynamics were correlated with the development of gadolinium-enhancing (Gd+) lesions...
May 14, 2024: Neurology